Stivarga (regorafenib) — Medica
Central nervous system tumors (glioblastoma, H3-mutated high-grade glioma)
Initial criteria
- age ≥ 18 years
- recurrent or progressive disease
- diagnosis of glioblastoma OR H3-mutated high-grade glioma
Approval duration
1 year